ArticleScientific reports2022
Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Treatment Outcomes ofOpen forum infectious diseases · 2025Trial
- Case - Penile mycobacterium avium complex infection.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Review
- Association between nutritional status and clinical characteristics in nontuberculous mycobacterial pulmonary disease: preliminary results from the NTM-KOREA cohort.Respiratory research · 2026Article
- Sputum Microbiome Based on the Etiology and Severity of Nontuberculous Mycobacterial Pulmonary Disease.Journal of clinical medicine · 2025Article
- Clinical Implications of Time to Culture Conversion inOpen forum infectious diseases · 2025Article
- Can the BACES score predict clinical outcomes in a Dutch cohort with nontuberculous mycobacterial pulmonary disease?ERJ open research · 2025Article
- TheMicroorganisms · 2025Review
- Developing a Simple Scoring System on CT Findings for Predicting Treatment Failure inOpen forum infectious diseases · 2025Article
- BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary disease.Scientific reports · 2025Article
- Inhibitors of acetohydroxyacid synthase as promising agents against non-tuberculous mycobacterial diseases.The Journal of antibiotics · 2025Article
- The Clinical Implications of Serum Carbohydrate Antigen 19-9 Levels in Patients with Nontuberculous Mycobacteria Pulmonary Disease.Journal of clinical medicine · 2023Article
- Spontaneous Cultural Conversion Rate ofJournal of clinical medicine · 2023Article
- Treatment outcomes and relapse in patients withMicrobiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium avium complex pulmonary disease (MAC-PD) requires long-term treatment. We analyzed the outcomes of 992 MAC-PD patients according to disease severity and compared the outcomes of intermittent and daily therapy for mild disease. Patients were divided into groups according to severity using the body mass index, age, cavity, erythrocyte sedimentation rate, and sex (BACES) system, and culture conversion rates were evaluated. We also evaluated the effects of intermittent treatment on the culture conversion rates in mild disease group. Using the BACES, 992 patients were divided into mild (n = 331), moderate (n = 503), and severe (n = 158) disease groups, and culture conversion at the end of treatment was achieved in 85% (282/331), 80% (403/503), and 61% (97/158), respectively. Differences in culture conversion among the severity groups were significant (p < 0.001). In patients with mild disease, culture conversion rates were similar between intermittent (84%, 166/198) and daily (87%, 116/133) treatment (p = 0.396), and intermittent antibiotic therapy did not negatively impact culture conversion (adjusted hazard ratio 1.08; confidence interval 0.83-1.41; p = 0.578). MAC-PD patients with mild disease had higher culture conversion rates. Daily and intermittent therapy yielded similar culture conversion rates for mild disease. Treatment strategies with lower pill burden may be applicable in mild MAC-PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.